Literature DB >> 27073576

Analysis of PI3K pathway components in human cancers.

Jamila Daragmeh1, Waseim Barriah2, Bashar Saad3, Hilal Zaid3.   

Abstract

Recent advances in genomics, proteomics, cell biology and biochemistry of tumors have revealed new pathways that are aberrantly activated in numerous cancer types. However, the enormous amount of data available in this field may mislead scientists in focused research. As cancer cell growth and progression is often dependent upon the phosphoinositide 3-kinase (PI3K)/AKT pathway, there has been extensive research into the proteins implicated in the PI3K pathway. Using data available in the Human Protein Atlas database, the current study investigated the expression of 25 key proteins that are known to be involved with PI3K pathway activation in a distinct group of 20 cancer types. These proteins are AKTIP, ARP1, BAD, GSK3A, GSK3B, MERTK-1, PIK3CA, PRR5, PSTPIP2, PTEN, FOX1, RHEB, RPS6KB1, TSC1, TP53, BCL2, CCND1, WFIKKN2, CREBBP, caspase-9, PTK2, EGFR, FAS, CDKN1A and XIAP. The analysis revealed pronounced expression of specific proteins in distinct cancer tissues, which may have the potential to serve as targets for treatments and provide insights into the molecular basis of cancer.

Entities:  

Keywords:  AKT; EGFR; Human Protein Atlas; PI3K; PTEN; TSC1; cancer; tumorigenesis

Year:  2016        PMID: 27073576      PMCID: PMC4812578          DOI: 10.3892/ol.2016.4309

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  42 in total

Review 1.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise.

Authors:  Ji Luo; Brendan D Manning; Lewis C Cantley
Journal:  Cancer Cell       Date:  2003-10       Impact factor: 31.743

2.  Arf and Rho GAP adapter protein ARAP1 participates in the mobilization of TRAIL-R1/DR4 to the plasma membrane.

Authors:  Sárka Símová; Martin Klíma; Lukas Cermak; Vladimíra Sourková; Ladislav Andera
Journal:  Apoptosis       Date:  2008-03       Impact factor: 4.677

3.  Prevalence and spectrum of PITX2c mutations associated with congenital heart disease.

Authors:  Juan Wang; Yuan-Feng Xin; Wen-Jun Xu; Zhong-Min Liu; Xing-Biao Qiu; Xin-Kai Qu; Lei Xu; Xin Li; Yi-Qing Yang
Journal:  DNA Cell Biol       Date:  2013-10-01       Impact factor: 3.311

Review 4.  PI3K/Akt signalling pathway and cancer.

Authors:  Juan Angel Fresno Vara; Enrique Casado; Javier de Castro; Paloma Cejas; Cristóbal Belda-Iniesta; Manuel González-Barón
Journal:  Cancer Treat Rev       Date:  2004-04       Impact factor: 12.111

Review 5.  Bcl-2 regulation of the inositol 1,4,5-trisphosphate receptor and calcium signaling in normal and malignant lymphocytes: potential new target for cancer treatment.

Authors:  Edward F Greenberg; Andrew R Lavik; Clark W Distelhorst
Journal:  Biochim Biophys Acta       Date:  2014-03-15

6.  X-chromosome-linked inhibitor of apoptosis as a key factor for chemoresistance in clear cell carcinoma of the ovary.

Authors:  M Miyamoto; M Takano; K Iwaya; N Shinomiya; M Kato; T Aoyama; N Sasaki; T Goto; A Suzuki; J Hitrata; K Furuya
Journal:  Br J Cancer       Date:  2014-05-22       Impact factor: 7.640

Review 7.  Activation of the PI3K/mTOR/AKT pathway and survival in solid tumors: systematic review and meta-analysis.

Authors:  Alberto Ocana; Francisco Vera-Badillo; Mustafa Al-Mubarak; Arnoud J Templeton; Verónica Corrales-Sanchez; Laura Diez-Gonzalez; María D Cuenca-Lopez; Bostjan Seruga; Atanasio Pandiella; Eitan Amir
Journal:  PLoS One       Date:  2014-04-28       Impact factor: 3.240

8.  Regulation of TORC1 in response to amino acid starvation via lysosomal recruitment of TSC2.

Authors:  Constantinos Demetriades; Nikolaos Doumpas; Aurelio A Teleman
Journal:  Cell       Date:  2014-02-13       Impact factor: 41.582

9.  PIP2 signaling, an integrator of cell polarity and vesicle trafficking in directionally migrating cells.

Authors:  Narendra Thapa; Richard A Anderson
Journal:  Cell Adh Migr       Date:  2012-09-01       Impact factor: 3.405

10.  Feedback loops blockade potentiates apoptosis induction and antitumor activity of a novel AKT inhibitor DC120 in human liver cancer.

Authors:  F Yang; R Deng; X-J Qian; S-H Chang; X-Q Wu; J Qin; G-K Feng; K Ding; X-F Zhu
Journal:  Cell Death Dis       Date:  2014-03-13       Impact factor: 8.469

View more
  11 in total

1.  Medicinal Plants and Natural Active Compounds for Cancer Chemoprevention/Chemotherapy.

Authors:  Hilal Zaid; Michael Silbermann; Alaa Amash; Dan Gincel; Essam Abdel-Sattar; Nazli B Sarikahya
Journal:  Evid Based Complement Alternat Med       Date:  2017-04-09       Impact factor: 2.629

2.  Immune oncology, immune responsiveness and the theory of everything.

Authors:  Tolga Turan; Deepti Kannan; Maulik Patel; J Matthew Barnes; Sonia G Tanlimco; Rongze Lu; Kyle Halliwill; Sarah Kongpachith; Douglas E Kline; Wouter Hendrickx; Alessandra Cesano; Lisa H Butterfield; Howard L Kaufman; Thomas J Hudson; Davide Bedognetti; Francesco Marincola; Josue Samayoa
Journal:  J Immunother Cancer       Date:  2018-06-05       Impact factor: 13.751

3.  Altered CSF Proteomic Profiling of Paediatric Acute Lymphocytic Leukemia Patients with CNS Infiltration.

Authors:  Fei Mo; Xuelei Ma; Xiaobei Liu; Ruofan Zhou; Yunuo Zhao; Hui Zhou
Journal:  J Oncol       Date:  2019-05-02       Impact factor: 4.375

4.  Cancer immune resistance: can theories converge?

Authors:  Rongze Lu; Tolga Turan; Josue Samayoa; Francesco M Marincola
Journal:  Emerg Top Life Sci       Date:  2017-12-12

5.  A balance score between immune stimulatory and suppressive microenvironments identifies mediators of tumour immunity and predicts pan-cancer survival.

Authors:  Tolga Turan; Sarah Kongpachith; Kyle Halliwill; Jessica Roelands; Wouter Hendrickx; Francesco M Marincola; Thomas J Hudson; Howard J Jacob; Davide Bedognetti; Josue Samayoa; Michele Ceccarelli
Journal:  Br J Cancer       Date:  2020-11-05       Impact factor: 7.640

6.  Evidence for the Involvement of COX-2/VEGF and PTEN/Pl3K/AKT Pathway the Mechanism of Oroxin B Treated Liver Cancer.

Authors:  Nan-Nan Li; Xian-Sheng Meng; Yong-Rui Bao; Shuai Wang; Tian-Jiao Li
Journal:  Pharmacogn Mag       Date:  2018-04-10       Impact factor: 1.085

7.  Long noncoding RNA HULC accelerates liver cancer by inhibiting PTEN via autophagy cooperation to miR15a.

Authors:  Xiaoru Xin; Mengying Wu; Qiuyu Meng; Chen Wang; Yanan Lu; Yuxin Yang; Xiaonan Li; Qidi Zheng; Hu Pu; Xin Gui; Tianming Li; Jiao Li; Song Jia; Dongdong Lu
Journal:  Mol Cancer       Date:  2018-06-12       Impact factor: 27.401

8.  Simultaneous targeting of HER family pro-survival signaling with Pan-HER antibody mixture is highly effective in TNBC: a preclinical trial with PDXs.

Authors:  Tejaswini P Reddy; Dong S Choi; Ann C Anselme; Wei Qian; Wen Chen; Johan Lantto; Ivan D Horak; Michael Kragh; Jenny C Chang; Roberto R Rosato
Journal:  Breast Cancer Res       Date:  2020-05-15       Impact factor: 6.466

9.  Persistent Rheb-induced mTORC1 activation in spinal cord neurons induces hypersensitivity in neuropathic pain.

Authors:  Xiaqing Ma; Wenjie Du; Wenying Wang; Limin Luo; Min Huang; Haiyan Wang; Raozhou Lin; Zhongping Li; Haibo Shi; Tifei Yuan; Wei Jiang; Paul F Worley; Tao Xu
Journal:  Cell Death Dis       Date:  2020-09-12       Impact factor: 8.469

10.  Apatinib enhances the anti-tumor effect of paclitaxel via the PI3K/p65/Bcl-xl pathway in triple-negative breast cancer.

Authors:  Jing Chen; Shuzhen Deng; Yifan Zhang; Chaokun Wang; Xiaochen Hu; Dejiu Kong; Gaofeng Liang; Xiang Yuan; Yuanpei Li; Xinshuai Wang
Journal:  Ann Transl Med       Date:  2021-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.